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Abstract
Introduction Chromosome arm 16q is the second most
frequent target of loss of heterozygosity in breast cancer and is,
therefore, a candidate to contain one or more classic tumour
suppressor genes (TSGs). E-cadherin at 16q22 was identified
as a TSG in lobular breast cancer, but TSGs in ductal breast
cancer remain elusive. Several genes have been suggested as
potential candidates (e.g. CBFA2T3, CTCF and WWOX) but
no inactivating mutations could be identified in these genes and
they thus fail to fit the classic two-hit model for a TSG. With the
completion of the human transcriptome, new candidate genes
can be distinguished. Besides mutational inactivation, a TSG
could, at least in a subset of the tumours, be transcriptionally
suppressed or even inactivated. Studying candidate genes for
expression and somatic mutations could thus identify the TSGs.
Methods Possible candidates CBFA2T3,  TERF2  and
TERF2IP, FBXL8 and LRRC29 and FANCA were studied for
insertion and deletion mutations and for expression differences
using quantitative RT-PCR in a panel of tumour cell lines and
primary tumours with and without loss of 16q.
Results None of the genes showed mutations or obvious
expression differences. FANCA  expression increased with
tumour grade.
Conclusion Apparently, the underlying genetics at chromosome
16q are complex or the TSGs remain to be identified. Multiple
mechanisms, such as mutations, promoter hypermethylation or
haploinsufficiency, might lead to the inactivation of a TSG.
Introduction
The long arm of chromosome 16 is a frequent target for loss
of heterozygosity (LOH) in sporadic breast cancer [1].
Detailed mapping of LOH revealed at least two frequently
deleted genomic regions on chromosome 16q22.1 and
16q24.3 that could harbour classical tumour suppressor
genes (TSGs) [2,3]. Mutation analysis identified the
homophilic epithelial cell adhesion gene CDH1 encoding E-
cadherin, located at 16q22.1, as a TSG, but only in the histo-
logical subset of lobular breast cancer and not in the more fre-
quent ductal breast cancer [4]. Thus, the TSGs in ductal
breast cancer remain elusive. To identify these TSGs, many
genes have already been screened and excluded as candi-
dates [5-8]. Although some studies have suggested other
genes as potential candidates (e.g. the transcriptional co-
repressor CBFA2T3 (MTG16) [9], the zinc finger transcription
factor CTCF [10] or the oxidoreductase WWOX [11]), these
genes fail to fit the classic two-hit model for a TSG because
no inactivating mutations could be identified in the retained
copy of them. Apparently the underlying genetics at chromo-
some 16q is more complex than originally conceived or the
TSGs remain to be identified [12]. Multiple mechanisms, such
as mutations, promoter hypermethylation or haploinsufficiency
might lead to the inactivation of a TSG [12]. Regardless of the
mechanism, however, it can be expected that the TSG will, at
least in a subset of the tumours, be transcriptionally sup-
pressed or even inactivated. Thus, studying candidate genes
for expression and somatic mutations could identify the TSGs.
Another problem that has hampered the identification of TSGs
is the nature of the smallest region of overlap (SRO) deter-
mined by LOH mapping. Indeed, the selection of candidate
LOH = loss of heterozygosity; qPCR = quantitative reverse transcriptase polymerase chain reaction; RFVI = relative fold variability index; SRO = small-
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tumour suppressor genes in previous studies is driven by the
exact location of a gene in the SRO. Unfortunately, consensus
on SROs is low and based on just a few tumours. The LOH
events in these tumours could be based on non-specific
genetic aberrations or even false-positive/negative LOH-call-
ing. In this study, we have selected genes that are located not
in the smallest region, but in the most common region, which
is much larger. The selection of these candidate genes is not
driven by their location but based on the function of the genes
that fit that of a tumour suppressor gene or the involvement of
these genes or their homologs in breast or other cancers. The
study was not restricted to mutational inactivation but
focussed on possible transcriptional down regulation.
With the completion of the human genome and gene maps
[13,14], other likely candidate genes on chromosome 16q
have appeared. Here we describe the gene-expression analy-
sis of new candidate genes in breast tumours.
Two interacting genes, TERF2  and  TERF2IP, which are
involved in telomere maintenance, reside on 16q22.1 and
16q23.1, respectively. These genes are interesting candi-
dates because, together with several other factors, they form
the TERF2 complex that is primarily involved in telomere main-
tenance [15]. TERF2 protects human telomeres from end-to-
end fusions [16] and TERF2IP has a role in the regulation of
telomere length distribution [17]. Decreased expression of
TERF2  was reported in leukaemia and in gastric cancer
[18,19], fitting a TSG function.
Two F-box proteins, FBXL8 and LRRC29, are located on chro-
mosome 16q22.1. F-box proteins determine substrate specif-
icity of the SCF complexes in ubiquitin-proteasome
proteolysis. Uncontrolled degradation of proteins may underlie
the development and progression of malignancies; a deletion
of the hCdc4 F-box protein was found in breast cancer [20-
22]. As two F-box proteins are located on 16q, these might be
potential TSG candidates.
Recently, the Fanconi anaemia complex was connected to
breast cancer; BRCA1 directly interacts with the Fanconi
pathway, of which BRCA2 was recently identified as one com-
ponent [23,24]. Although we previously excluded FANCA,
located on 16q24, as a classic TSG by mutation analysis [5],
other mechanisms could lead to inactivation of FANCA. We
therefore included FANCA in the expression analysis to detect
possible loss of expression in breast tumours.
We used quantitative reverse transcriptase PCR (qPCR) to
perform expression studies on these genes in a panel of breast
cancer cell lines and primary breast tumours with defined LOH
status at chromosome 16q [3,25,26]. For the proper normali-
zation of the expression levels in qPCR studies, we selected
new control genes. These genes were selected from expres-
Table 1
Mammary cell lines and tumours
LOH 16q status
Mammary cell lines
BT20 LOH 16q24
BT474 Retention
BT483 Retention
BT549 LOH 16q
CAMA LOH 16q
Du4475 Retention
HBL100 Retention
HS578t LOH 16q22
MCF10A -
MCF10F -
MCF12A -
MCF7 Retention
MDA-MB-134 LOH 16q
MDA-MB-157 LOH 16q24
MDA-MB-175 Retention
MDA-MB-231 LOH 16q
MDA-MB-330 Retention
MDA-MB-361 Retention
MDA-MB-435 Retention
MDA-MB-453 LOH 16q24
MDA-MB-468 LOH 16q
MPE600 LOH 16q
OCUBF LOH 16q
SKBR3 LOH 16q
SKBR5 LOH 16q
SUM185 LOH 16q
Sum44PE LOH 16q
SUM52 LOH 16q
T47d LOH 16q
ZR75 LOH 16q
Primary breast tissues numbers
2N o r m a l  b r e a s t
11 Retention
15 LOH 16q
9 LOH 16q21-ter
3 LOH 16q22
2 LOH 16q24
LOH, loss of heterozygosity.Available online http://breast-cancer-research.com/content/7/6/R998
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sion data generated by microarray experiments by picking the
most stably expressed genes from these experiments.
Materials and methods
Material and RNA isolation
Cell lines, listed in Table 1, were obtained from ATCC, except
for the MPE600 (provided by Dr F Waldman, California Pacific
Medical Center), SKBr5 (provided by Dr E Stockert, Sloan-
Kettering Institute) and Sum44PE and Sum185PE (provided
by Dr SP Ethier). OCUB-F was obtained from the Riken Gene
Bank. All cell lines were grown in RPMI culture medium
(Gibco-BRL, Grand Island,. NY, USA) with 5 mM glutamine/
10% fetal calf serum at 37°C under 5% CO2, and harvested
at 70% to 80% confluence for RNA isolation. LOH and phys-
ical status on chromosome 16 for these cell lines was pub-
lished previously [25,27].
From a series of fresh frozen breast tumours, tested for LOH
on the long arm of chromosome 16 as described previously
[3], we selected a representative panel of tumours with differ-
ent LOH status at chromosome 16q and with at least 50%
tumour cells on examination of a hematoxylin and eosin-
stained section by a pathologist. The series consists of 189
patients operated on between 1986 and 1993 in three Dutch
hospitals [3]. Patient material was obtained on approval of
local medical ethics committees. RNA from cell lines and
snap-frozen tumours was isolated using TRIZOL (Invitrogen,
Breda, The Netherlands) and subsequently purified with Qia-
gen RNeasy columns combined with the RNase-free DNase
kit (Qiagen Sciences, Germantown, MD, USA) according to
the manufacturer's instructions. cDNA was made using AMV
reverse transcriptase (Roche Diagnostics, Basel,
Switzerland).
Quantitative reverse transcriptase PCR
qPCR primers were designed in Primer Express (Applied Bio-
systems Applied Biosystems, Foster City, CA, USA) and prim-
ers for fragment analysis were designed using the primer3
program [28]. qPCR reactions were performed on an iCycler
(Biorad, Hercules, CA, USA) using the SybrGreen qPCR
core-kit (Eurogentec, Seraing, Belgium). Cycle conditions
were: 10 minutes at 94°C followed by 40 cycles of 10 s at
94°C and 1 minute at 60°C. Cycle threshold extraction was
performed using the iCycler IQ software (version 3, Biorad).
The primers used were: CPSF6, 5'-AAGATTGCCTTCAT-
GGAATTGAG-3', 5'-TCGTGATCTACTATGGTCCCTCTCT-
3';  CYPA, 5'-TCATCTGCACTGCCAAGACTG-3', 5'-CAT-
GCCTTCTTTCACTTTGCC-3'; FANCA, 5'-TTAATACCTCG-
GTGCCCGAA-3', 5'-AGTCCCCACGATCAGCCA-3';
LRRC29, 5'-CCTGCACGCCTGCCC-3', 5'-TGCAGT-
CAGCTCATAGAGCAGACACTGGA-3';  HNRPM, 5'-GAG-
GCCATGCTCCTGGG-3', 5'-
TTTAGCATCTTCCATGTGAAATCG-3';  CBFA2T3, 5'-
ACATCTGGAGGAAGGCTGAAGAG-3', 5'-GCTCCATCTT-
GGCACGCT-3';  PFKP, 5'-ACCCCTTCGGCATTCGAC-3',
5'-AGCAAGGCGATGACTGCC-3';  TERF2IP, 5'-AAGCT-
CAAGCGGAAGGCG-3', 5'-TCTGGAGTTCTCTTATTCT-
GTGGTTC-3'; TAF1C, 5'-GACCGCACCGGAGTGAAG-3',
5'-AACGAAAAAGCAACAGACCACA-3'; and TERF2, 5'-
GGTACGGGGACTTCAGACAG-3', 5'-CGCGACA-
GACACTGCATAAC-3'. For all PCRs, a standard curve was
generated using five 1:5 dilutions of pooled cDNA from normal
breast epithelial cell lines (MCF10A, MCF10F, MCF12). Rela-
tive concentrations of mRNA for each gene were calculated
from the standard curve. After qPCR, dissociation curves were
made to check the quality of the reaction. Reactions with more
than one peak in the dissociation curve were discarded. Using
the GeNorm applet, stably expressed control genes for nor-
malization were selected; the three most stable expressed
Figure 1
Quantitative reverse transcriptase PCR expression analysis in breast  cancer cell lines and tumours Quantitative reverse transcriptase PCR expression analysis in breast 
cancer cell lines and tumours. Expression analysis in (a) breast cancer 
cell lines and (b) breast tumours stratified according to their loss of het-
erozygosity (LOH) status on the long arm of chromosome 16.Breast Cancer Research    Vol 7 No 6    van Wezel et al.
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genes were used to calculate normalization factors for each
cell line or tumour cDNA [29]. For normalization, the highest
expression values for each gene were set to 1 and subse-
quently divided by the normalization factor generated by the
GeNorm applet.
Alternatively, we calculated the rlative fold variability index
(RFVI) for each gene, as described [30]. The baseline RFVIs
were calculated for the control genes CPSF6, HNRPM, TBP
and  CYPA. These ranged between 11 and 42, reflecting
experimental or population variations.
Fragment analysis
Standard fragment analysis on genomic DNA was performed
using fluorescent-labelled primers (Isogen Life Science, IJssel-
stein, The Netherlands) on an ABI377 and analysed using
GeneScan and Genotyper software (Applied Biosystems).
Sequencing was performed at the sequence core of the Lei-
den Genome Technology Center. Four genes were screened
to detect small insertions and deletions. Products ranging
from 200 to 500 base pairs were generated to screen the
exons of TERF2IP, TERF2, LRRC29 and FBXL8 (4, 10, 4 and
6 products, respectively). Fluorescent fragment analysis
detects most if not all insertions and deletions due to the size
differences and detection of mutations varies from 60% to
88% [31,32].
Results and discussion
Quantitative reverse transcriptase PCR expression 
analysis
RNA expression of the candidate TSGs at the frequently
deleted long arm of chromosome 16 (FANCA,  TERF2IP,
TERF2,  FBXL8, LRRC29  and CBFA2T3  [9]) was studied
using qPCR. Expression of the genes in normal breast tissue
is a prerequisite for a function as a TSG. We therefore first
tested the expression by qPCR in three normal breast cell lines
and two normal breast tissues. FANCA, TERF2IP, TERF2,
LRRC29 and CBFA2T3 were expressed in breast tissue. For
FBXL8, however, we failed to show any expression in normal
breast, breast cell lines or breast tumours using different com-
binations of RT-PCR primers or northern blot analysis (not
shown). We therefore excluded FBXL8 from any further anal-
ysis and as a candidate TSG. Expression analysis of the genes
was studied using real-time qPCR. Relative expression levels
of the genes for each sample were calculated from a standard
curve from the pooled normal breast cell lines, MCF10A,
MCF10F and MCF12A.
Control genes for normalization
For accurate normalization of qPCR data, multiple stably
expressed control genes are required [29] because expres-
sion variations in a single control gene could have significant
impact on the relative expression levels of genes under study.
Several control genes are widely used for normalization, such
as HPRT (encoding hypoxanthine phosphoribosyl transferase
1), GAPDH (encoding glyceraldehyde-3-phosphate dehydro-
genase),  TBP  (encoding TATA box binding protein) and
PBGD  (encoding porphobilinogen deaminase or
hydroxymethylbilane synthase) [29]. The use of CYPA (encod-
ing cyclophilin A or peptidylprolyl isomerase A) has also been
reported for normalization of breast cancer cell lines using
qPCR [30].
For each qPCR experiment, the optimal set of controls needs
to be tested and the most used controls are not necessarily
the best controls. To identify additional control genes specifi-
cally suitable for breast cancer cell lines and tumours, we
selected possible control genes from gene-expression micro-
arrays hybridised with breast cancer cell lines (Lombaerts,M.,
van Wezel,T., Philippo,K., Dierssen,J.W.F., Zimmerman,R.M.E.,
Oosting,J., van Eijk,R., Eilers,P.H., Van De Water,B., Cor-
nelisse,C.J., and Cleton-Jansen,A.M.manuscript submitted).
From these cDNA arrays, the most stably expressed possible
control genes with the least expression variation in multiple
breast cancer cell lines were selected. These were CPSF6
(encoding cleavage and polyadenylation specific factor 6),
HNRPM (encoding heterogeneous nuclear ribonucleoprotein
M),  PFKP  (encoding the phosphofructokinase PFKP) and
TAF1C (encoding TBP-associated factor, RNA polymerase
IC).  CPSF6,  HNRPM,  PFKP  and  TAF1C, together with
HPRT, GAPDH, TBP, PBGD and CYPA, were compared for
expression stability in the panel of breast cancer cell lines.
Four colon tumour cell lines LS411, LS180, SW480 and
Table 2
Stability factor M for cell lines and tumours
Rank Control gene M
Cell lines
1 CPSF6 0.58
1 CYPA 0.58
2 TBP 0.83
3 HNRPM 1.08
4 PBGD 1.18
5 TAF1C 1.27
6 HPRT 1.47
7 GAPD 1.75
8 PFKP 1.96
Tumours
1 CPSF6 0.38
1 HNRPM 0.38
2 TBP 0.54
3 CYPA 0.65
4 HPRT 0.69Available online http://breast-cancer-research.com/content/7/6/R998
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SW837 were also included. The most stable control genes for
normalization of the relative concentrations of mRNA were
identified using the GeNorm software [29]. In the panel of
breast cancer cell lines, the most stably expressed genes were
TBP, CYPA and CPSF6 (Fig. 1), and in the colon cancer cell
lines, CPSF6, HNRPM and TBP appeared the most stably
expressed genes (data not shown). For the breast tumours, we
tested only the genes HPRT,  CYPA,  TBP,  CPSF6  and
HNRPM as the availability of tumour RNA is limited. GeNorm
calculates the stability factor 'M' of all control genes by com-
paring the variation in expression for all genes. A low M-value
represents low variation in expression. Table 2 lists the stability
factors for all control genes tested. CPSF6, CYPA and TBP
were the most stable and were used in subsequent experi-
ments. The commonly used control genes HPRT and GAPDH
are much more variable and less suitable as control genes in
breast tumours.
The identification of control genes for the normalization of
qPCR experiments proved useful as both CPSF6  and
HNPRM were very stably expressed in both breast cancer cell
lines and tumours. In general, the control genes were more
stable in the tumours than in the cell lines (for CPSF6, M =
0.58 for the cell lines and M = 0.38 in tumours). This is possi-
bly due to multiple cell types that are present in a tumour
(tumour and stromal cells and infiltrating lymphocytes)
whereas cell lines usually are monocultures.
Expression study in cell lines and tumours
We used a panel of three normal breast cell lines (MCF10A,
MCF10F and MCF12A), and 27 breast cancer cell lines
(Table 1), 1 with LOH q22, 3 with LOH q24, 9 with retention
of 16q and 14 with loss of 16q [25,27]. Furthermore, we
tested a panel of two normal breast samples and 40 breast
tumours with loss of (part of) the q-arm or with retention of 16q
(Table 1). Expression values were normalized by a factor cal-
culated from the three most stable control genes for the cell
lines and tumours, (Table 2). Additionally, we calculated the
RFVI for each gene between the samples with the highest and
lowest expression, using the base-line expression value of
each gene in normal breast tissue or cell line, as described
previously [30]. The baseline RFVI for the control genes
CPSF6, HNRPM, TBP and CYPA ranged between 11 and
42, reflecting experimental or population variations.
As FBXL8 expression could not be detected, this gene was
not included in further analysis. LRRC29 was tested first in the
cell lines (Fig. 1a). This showed no difference between cell
lines with and without LOH, and also the RFVI index for
LRRC29 was below the baseline (Fig. 2). These data exclude
LRRC29 as a candidate gene and LRRC29 expression was,
therefore, not studied in the tumours.
Both TERF2IP and TERF2 show somewhat reduced levels of
expression in cell lines with LOH of chromosome arm 16q
when compared with those with 16q retention (Fig. 1a); how-
ever, these differences are not significant. Both genes were
subsequently tested in the tumour panel; again, slightly
reduced expression was detected in samples with LOH (Fig
1b). However, the expression was also reduced in tumours
with loss of 16q24 alone whereas TERF2IP and TERF2 are
located on 16q22. The expression appears to be lower in all
tumours compared to normal tissue, regardless of LOH or
even grade (data not shown). Also, RFVI levels for TERF2IP
and TERF2 are 38 and 41, respectively, which are in the same
range as the housekeeping control genes (i.e. below the
Figure 2
Relative fold variability index (RFVI) of the analysed candidate genes in  breast tumours (hatched bars) and breast cancer cell lines (grey bars) Relative fold variability index (RFVI) of the analysed candidate genes in 
breast tumours (hatched bars) and breast cancer cell lines (grey bars). 
Only FANCA and CBFA2T3 in cell lines display levels above the 
baseline.
Figure 3
Quantitative reverse transcriptase PCR expression analysis in breast  tumours according to tumour grade Quantitative reverse transcriptase PCR expression analysis in breast 
tumours according to tumour grade.Breast Cancer Research    Vol 7 No 6    van Wezel et al.
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baseline level). Based on their gene expression variation,
therefore, neither genes are likely to be candidate TSGs.
CBFA2T3 encodes a translocation partner of AML1 in mye-
loid leukaemia and a transcription repressor. Based on its
location on chromosomal band 16q24.3, high variation in
expression in breast cancer cell lines, loss of protein expres-
sion in breast tumours and in vitro growth inhibition of breast
cancer cell lines, CBFA2T3 has been proposed as a candi-
date TSG [9,30]. We therefore tested this gene in our panel
of cell lines and tumours to confirm this finding. We found a
large expression variation for CBFA2T3 in cell lines, resulting
in a high RFVI value of 122 (Fig. 2), which, however, was not
associated with LOH at 16q (Fig. 1a). In primary tumours,
there was a tendency for higher CBFA2T3  expression in
tumours with LOH of 16q24 (Fig. 1b), where this gene is
located, and the RFVI value was below the baseline. These
data do not support the candidacy of CBFA2T3 as a TSG on
16q.
FANCA is involved in DNA repair and located at 16q24.3. Its
expression in tumours is higher than in normal tissue and,
remarkably, expression increases with tumour grade (Fig. 3).
There is no association between LOH at 16q and tumour
grade, but there is a difference in the mechanism of LOH when
comparing low- and high-grade breast cancers. Whereas low-
grade tumours show preferential physical loss of 16q, high-
grade tumours show mitotic recombination [33]. This could
indicate that FANCA  is involved only in well differentiated
breast cancer. In cell lines, FANCA levels are slightly reduced
in tumours with LOH. Interestingly, in tumours with loss of the
complete q-arm, FANCA expression is lower than in those
with retention of 16q. In those with loss of q21-ter, however,
expression is higher than in tumours with retention, suggesting
again that the mechanism of 16q LOH may be associated with
the targeted TSG.
Fragment analysis
TERF2IP, TERF2, FBXL8 and LRRC29 were screened using
fragment analysis for (small) genomic deletions or insertions in
their exons in 21 breast cancer cell lines and 32 breast
tumours. CBFA2T3 and FANCA were previously screened for
mutations, without identifying any inactivating or somatic muta-
tions [5,9]. Although TSGs are, in many cases, inactivated
through deletions and insertions, no mutations were found.
Conclusion
We studied CBFA2T3, FANCA,  FBXL8, LRRC29,  TERF2
and  TERF2IP, six potential breast cancer TSG candidate
genes located on the long arm of chromosome 16, which is
involved in LOH in more than 50% of breast cancer cases.
These genes were studied using qPCR to detect possible
transcriptional down-regulation in a representative panel of
breast cancer cell lines and primary tumours with well defined
patterns of LOH at chromosome 16q. For reliable qPCR, two
new, stable control genes for normalization of qPCR experi-
ments,  HNRPM  and  CPSF6, were identified. We did not
detect any significant difference in expression of the candidate
genes related to the LOH status of tumours and cell lines.
Mutation analysis of these genes did not reveal inactivating,
tumour specific alterations. Therefore, these genes are unlikely
to be candidates for the classic tumour suppressor gene on
chromosome 16q. The identification of the underlying tumour
suppressor genes and their mechanisms of inactivation
remains a difficult task. New insights into neoplastic transfor-
mation indicate that somatic tumour genetics are far more
complex than originally conceived, involving multiple non-clas-
sic TSGs with individual small effects [34,35]. Successful
identification of these genes requires an integrated genomic
approach, combining the analysis of LOH, copy number
changes and expression studies.
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